Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 8658 [2018-04066]

Download as PDF 8658 Federal Register / Vol. 83, No. 40 / Wednesday, February 28, 2018 / Notices any given form identified by docket number, form number, and title. FOR FURTHER INFORMATION CONTACT: DEPARTMENT OF DEFENSE To request more information on this proposed information collection or to obtain a copy of the proposal and associated collection instruments, please write to the to the Department of the Army, Institute for Water Resources, Corps of Engineers Waterborne Commerce Statistics Center, P.O. Box 61280, ATTN: Christopher (Dale) Brown, New Orleans, LA 70161–1280, or call Department of the Army Reports Clearance Officer at (703) 428–6440. sradovich on DSK3GMQ082PROD with NOTICES SUPPLEMENTARY INFORMATION: Title; Associated Form; and OMB Number: Service Members Transitioning from Active Duty to Veterans Status; OMB Control Number 0702–XXXX. Needs and Uses: This study, exploratory in nature, is designed to capture baseline data prior to transition and at three subsequent data points after the transition out of service. The purpose of data capture before, during, and after transition is to allow the researchers to monitor how transition stressors change over time and what factors might influence their course. This information will be enormously useful in attempts to design and implement interventions that might target these stressors. Participants will be recruited during a set nine month window in which Service Members have self-identified as transitioning out of the service within the six months. Participation in the study is voluntary and participants will be consented twice, once at baseline (time point 1) while the Service Member is still active duty and then again at time point 2 as civilians. This burden information only accounts for the public being affected. Affected Public: Individuals and Households. Annual Burden Hours: 350 Hours. Number of Respondents: 600. Responses per Respondent: 1. Annual Responses: 600. Average Burden per Response: 35 minutes. Frequency: Annually. Dated: February 23, 2018. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2018–04059 Filed 2–27–18; 8:45 am] BILLING CODE 5001–06–P VerDate Sep<11>2014 17:25 Feb 27, 2018 Jkt 244001 Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting Under Secretary of Defense for Personnel and Readiness, Department of Defense. ACTION: Notice of Federal Advisory Committee meeting. AGENCY: The Department of Defense (DoD) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel will take place. DATES: Open to the public Thursday, April 5, 2018 from 9:00 a.m. to 12:00 p.m. SUMMARY: The address of the open meeting is the Naval Heritage Center Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, U.S. Navy, 703– 681–2890 (Voice), None (Facsimile), dha.ncr.health-it.mbx.baprequests@ mail.mil (Email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042–5101. Website: https://www.health.mil/About-MHS/ Other-MHS-Organizations/BeneficiaryAdvisory-Panel. The most up-to-date changes to the meeting agenda can be found on the website. SUPPLEMENTARY INFORMATION: This meeting is being held under the provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102–3.140 and 102–3.150. The Panel will review and comment on recommendations made to the Director of the Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. Purpose of the Meeting: The Department of Defense is publishing this notice to announce a Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). Agenda: Meeting Agenda: 1. Sign-In. 2. Welcome and Opening Remarks. 3. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item). a. Diabetes Non-Insulin: Glucagon-Like Peptide 1 Receptor Agonists Subclass. b. Osteoporosis Drugs: Parathyroid Hormone (PTH) Analog Subclass. c. Anti-Inflammatory Immunomodulatory Ophthalmic ADDRESSES: PO 00000 Frm 00010 Fmt 4703 Sfmt 4703 Agents—Ophthalmic Immunomodulatory Agents Subclass. d. Corticosteroids-Immune Modulators— Adrenocorticotropic Hormones Subclass. 4. Newly Approved Drugs Review. 5. Pertinent Utilization Management Issues. 6. Panel Discussions and Vote. Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 Code of Federal Regulations (CFR) 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. Written Statements: Pursuant to 41 CFR 102–3.140, the public or interested organizations may submit written statements to the membership of the Panel about its mission and/or the agenda to be addressed in this public meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained previously in this announcement. Written comments or statements must be received by the committee DFO at least five (5) business days prior to the meeting so that they may be made available to the Panel for its consideration prior to the meeting. The DFO will review all submitted written statements and provide copies to all the committee members. Dated: February 23, 2018. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2018–04066 Filed 2–27–18; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Office of the Secretary [Docket ID: DOD–2018–OS–0006] Proposed Collection; Comment Request Defense Finance and Accounting Service, DoD. ACTION: Information collection notice. AGENCY: In compliance with the Paperwork Reduction Act of 1995, the Defense Finance and Accounting Service announces a proposed public information collection and seeks public comment on the provisions thereof. Comments are invited on: Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; the accuracy of the SUMMARY: E:\FR\FM\28FEN1.SGM 28FEN1

Agencies

[Federal Register Volume 83, Number 40 (Wednesday, February 28, 2018)]
[Notices]
[Page 8658]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04066]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense.

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense (DoD) is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

DATES: Open to the public Thursday, April 5, 2018 from 9:00 a.m. to 
12:00 p.m.

ADDRESSES: The address of the open meeting is the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, U.S. Navy, 703-
681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington 
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date changes to the meeting agenda can be found 
on the website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    The Panel will review and comment on recommendations made to the 
Director of the Defense Health Agency, by the Pharmacy and Therapeutics 
Committee, regarding the Uniform Formulary.
    Purpose of the Meeting: The Department of Defense is publishing 
this notice to announce a Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel).
    Agenda: Meeting Agenda: 1. Sign-In. 2. Welcome and Opening Remarks. 
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item). a. Diabetes Non-Insulin: Glucagon-Like Peptide 1 Receptor 
Agonists Subclass. b. Osteoporosis Drugs: Parathyroid Hormone (PTH) 
Analog Subclass. c. Anti-Inflammatory Immunomodulatory Ophthalmic 
Agents--Ophthalmic Immunomodulatory Agents Subclass. d. 
Corticosteroids-Immune Modulators--Adrenocorticotropic Hormones 
Subclass. 4. Newly Approved Drugs Review. 5. Pertinent Utilization 
Management Issues. 6. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel about its mission and/or the agenda to be 
addressed in this public meeting. Written statements should be 
submitted to the Panel's Designated Federal Officer (DFO). The DFO's 
contact information can be obtained previously in this announcement. 
Written comments or statements must be received by the committee DFO at 
least five (5) business days prior to the meeting so that they may be 
made available to the Panel for its consideration prior to the meeting. 
The DFO will review all submitted written statements and provide copies 
to all the committee members.

    Dated: February 23, 2018.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2018-04066 Filed 2-27-18; 8:45 am]
BILLING CODE 5001-06-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.